Category: MDRO

The Trojan Horse of Antibiotics

I reckon it’s time to write about new antibiotics. I do not like beta-lactamases. Mostly due to their ability to confuse clinicians, however also because it makes it difficult to pick an antibiotic for certain infections. I have written extensively about these, so look at this post. In general, carabepenemases and cephalosporinases within class A

Continue reading

Ahorita-que? The New Gram Positive Antibiotic, Oritavancin

Vancomycin is the work-horse antibiotic every person reaches for. It is a glycopeptide that covers a wide range of gram positive bacteria, with its niche being in its coverage of methicillin-resistant staphylococcus aureus and Enterococcus spp. It is bacteriostatic, with dosing issues and highly nephrotoxic, however it is ubiquitous throughout any hospital in the United

Continue reading

The Microbiology of Diabetic Foot Infections – What I Didn’t Know

This and (likely) the next post are a product of questions I got asked. For instance, do you need anaerobic coverage for diabetic foot infections? Depends, but see later. What organisms do you need to cover for cellulitis in those who have had water exposure? Cephalexin and quinolones, with some exceptions. We will talk about

Continue reading

ESBL Infections: A Conundrum Yet to be Figured Out

Extended spectrum-beta lactamase producing organisms are those gram negatives that make beta-lactamases that inhibit third and fourth generation cephalosporins. As such, things such as piperacillin-tazobactam tends to show up as susceptible in antibiograms, however there has been a push lately towards the use of carbapenems as therapy for infections with these organisms. It seems kind

Continue reading

What to do with MDR Acinetobacter Baumannii?

Here in the DrGermophile ranks, we talk about all beta-lactamases and how awesome they are. In particular, we like sulbactam. It is in combination with ampicillin, and its use is unappreciated to the uninitiated, but it plays a role in infections such as anaerobic pneumonia. It has a reasonably broad spectrum of activity, losing out

Continue reading

Resistance is Futile, For Now – Overcoming Resistance with Ceftazidime-Avibactam

I think we can all agree that resistance is inevitable, despite what the quote says, in the world of infectious diseases. More and more, the use of broad spectrum antibiotics (looking at you, vanco-zosyn!) brings upon more resistant organisms, with beta-lactamases being one of the key methods of resistance in many gram negative bacteria. As

Continue reading

Emergence of the New Menace! Candida Auris and the Rise of MDR Yeasts.

Ear yeast! That is the translation of Candida auris. It was discovered by isolation from an ear infection in an elderly patient in Japan in 2009 and since then it has been isolated in places such as India, southeast Asia and several parts of south America (1-4):  One of the defining characteristics is its resistance

Continue reading

MDRO, DTR, WTF? Defining drug-resistance in Gram Negative Organisms

Gram negatives are a nightmare. Or at least, they are becoming a nightmare with all new patterns of resistance, beta-lactamases and carbapenamases, and plasmid-encoded resistances bringing forth the new generation of beta-lactam and beta-lactamase combinations that I find difficult to keep up with. The definitions of multi-drug resistant organisms tend to be more geared towards

Continue reading

What To Do With Stenotrophomonas?

If you get nothing from this, just remember: TMP-SMX, fluroquinolones, minocycline. These tend to be good antibiotic options for this bug. Also, make sure if you isolate this from a trach or a endotracheal tube that there are signs of infection before you proceed with treatment as this can colonize plastic! Stenotrophomonas maltophilia is a

Continue reading